Betanis mirabegron regulatory update

FDA's Reproductive Health Drugs Advisory Committee will meet on April 5 to discuss an NDA from Astellas for mirabegron to treat overactive bladder (OAB). The PDUFA date is June 29. The adrenergic rec...